| Literature DB >> 32046334 |
Uyen Thi Trang Than1, Dominic Guanzon2, James A Broadbent3, Tony J Parker2,3, David I Leavesley3,4.
Abstract
Extracellular membrane vesicles (EVs) have emerged as potential candidates for diagnostics and therapeutics. We have previously reported that keratinocytes release three types of EVs into the extracellular environment. Importantly, those EVs contain a large number of microRNAs (miRNAs) as cargo. In this study, we examined the expression level of keratinocyte-derived EV miRNAs, their target genes and potential functions. Next generation sequencing results showed that over one hundred miRNAs in each EV subtype exhibited greater than 100 reads per million (RPM), indicating a relatively high abundance. Analysis of the miRNAs with the highest abundance revealed associations with different keratinocyte cell sources. For instance, hsa-miR-205 was associated with the HaCaT cells whereas hsa-miR-21, hsa-miR-203, hsa-miR-22 and hsa-miR-143 were associated with human primary dermal keratinocytes (PKCs). Additionally, functional annotation analysis of genes regulated by those miRNAs, especially with regard to biological processes, also revealed cell-type-specific associations with either HaCaTs or PKCs. Indeed, EV functional effects were related to their parental cellular origin; specifically, PKC-derived EVs influenced fibroblast migration whereas HaCaT-derived EVs did not. In addition, the data in this current study indicates that keratinocyte-derived EVs and/or their cargoes have potential applications for wound healing.Entities:
Keywords: extracellular membrane vesicle; keratinocytes; microRNA; wound healing
Year: 2020 PMID: 32046334 PMCID: PMC7036882 DOI: 10.3390/ijms21031141
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Number of highly abundant extracellular membrane vesicle (EV) miRNAs with reads per million (RPM) greater than 100 and greater than 1000.
| Parental Cell Types | AP | MV | EX | |
|---|---|---|---|---|
|
| >100 RPM | 181 | 186 | 189 |
| >1000 RPM | 78 | 78 | 69 | |
|
| >100 RPM | 210 | 214 | 210 |
| >1000 RPM | 82 | 81 | 79 |
The relative abundance levels of the five most abundant miRNAs from HaCaT and primary keratinocyte-derived EVs.
|
| |||||
|
|
|
| |||
|
|
|
|
|
|
|
| hsa-miR-205-5p | 106,506.6 ± 8267.9 **** | hsa-miR-205-5p | 123,329.2 ± 44,355.9 *** | hsa-miR-205-5p | 100,832.8 ± 16,630.3 * |
| hsa-miR-22-3p | 92,576.7 ± 16,680 **** | hsa-miR-27b-3p | 60,380.3 ± 11,723.7 ** | hsa-miR-22-3p | 77,505.6 ± 14,611.1 * |
| hsa-miR-27b-3p | 57,661.6 ± 7889.6 **** | hsa-miR-22-3p | 59,791.6 ± 4818.9 ** | hsa-miR-27b-3p | 51,490.9 ± 237.7 *** |
| hsa-miR-21-5p | 49,946.5 ± 6634.3 ***** | hsa-miR-21-5p | 45,496.7 ± 3357 *** | hsa-miR-21-5p | 49,943.9 ± 4831.5 *** |
| hsa-miR-181a-1-5p | 48,805.9 ± 1721.1 ***** | hsa-miR-181a-1-5p | 45,541.5 ± 3393.9 *** | hsa-miR-92a-1-3p | 37,858.4 ± 523.1 **** |
|
| |||||
|
|
|
| |||
|
|
|
|
|
|
|
| hsa-miR-22-3p | 139,339.8 ± 43,597.7 *** | hsa-miR-22-3p | 93,878.6 ± 29,984.7 *** | hsa-miR-22-3p | 111,055.9 ± 9430.8 ****** |
| hsa-miR-21-5p | 81,954.5 ± 31,594.6 | hsa-miR-21-5p | 86,901.3 ± 21,422.5 | hsa-miR-21-5p | 110,112.7 ± 15,649.5 |
| hsa-miR-143-3p | 42,915.2 ± 24,838.4 ** | hsa-miR-143-3p | 38,016.7 ± 17,012.7 ** | hsa-miR-27b-3p | 52,399.1 ± 8430.5 **** |
| hsa-miR-203a-3p | 40,830.8 ± 7053.9 ** | hsa-miR-27b-3p | 45,115.2 ± 3168.5 * | hsa-miR-203a-3p | 49,640.4 ± 10,579.5 **** |
| hsa-miR-27b-3p | 40,707.7 ± 12,724.9 ** | hsa-miR-203a-3p | 34,067.1 ± 13,381.3 ** | hsa-miR-205-5p | 44,981.6 ± 10,617.4 ***** |
MN counts: Mean of normalised read counts from biological repeats using the RPM method. RPM: Read Per Million. SD: Standard Deviation. Statistical significance was determined by ANOVA and Post-hoc Tukey HSD tests, and is indicated by * where p < 0.05; ** where p < 0.01; *** where p < 0.001; **** where p < 0.0001; ***** where p < 0.00001; ****** where p < 0.000001.
Figure 1miRNA-205 is more associated with HaCaT cells and miRNA-21, miRNA-203, miRNA-22 and miRNA-143 are more associated with PKCs. Identified miRNAs from: (A) APs; (B) MVs; and (C) EXs. Biological replicates for HaCaT (n = 2) and PKCs (n = 4).
Figure 2Network of target genes regulated by (A) hsa-miR-205 and (B) by a group of four miRNAs, including hsa-miR-21, hsa-miR-203, hsa-miR-22 and hsa-miR-143. Inset table indicates gene groupings regulated by at least (B1) three or (B2–B7) two miRNAs.
Functional classification of genes regulated by hsa-miR-205.
| Group (Enrichment Score) | Genes | Biological Function |
|---|---|---|
| Group 1 (2.72) | MAP3K9, NEK9, ICK, STK38L | Protein kinase, protein phosphorylation, binding, nucleus, cytosol, cytoplasm, membrane |
| Group 2 (2.01) | BCL6, ZEB1, ZRB2, YY1, PLAGL2 | Zinc finger, zinc, repressor, activator, transcription, binding, nucleus |
| Group 3 (1.08) | SLC38A1, TMEM123, PAPPA-AS1, F2RL2, ENPP4, MMD, LYMSMD3, SLC5A12, SHISA6, NIPA2, TM9SF2, LRRTM4, SLC39A14, TMEM201, SMIM13, TMEM239, SERINC3, PRRG4, MANMI | Plasma membrane, transmembrane, topological domain: cytoplasmic, topological domain: extracellular, blood coagulation and haemostasis |
Functional classification of genes regulated by a group of four miRNAs, including hsa-miR-21, hsa-miR-203, hsa-miR-22 and hsa-miR-143, which are highly correlated with PKCs.
| Group (Enrichment Score) | Genes | Biological Function |
|---|---|---|
| Group 1 (27.64) | PLEKHA2, NUDCD1, ELP5, FILIP1L, NUFIP2, SERBP1, SSFA2, DAZAP2, HYPK, MYCBP, TSC22D4 | Cytoplasm, nucleus, protein binding, phosphoprotein |
| Group 2 (19.96) | ZBTB44, FAM208A, FOXK2, VGLL4, ZBTB8A, MAFK, MGA, LRRFIP1, MED9, NFAT5, ZNF654, ARID3B, MYCBP, HEXIM1, FOXN3, TAF1D, ATF7IP, DNTTIP2, CSRNP2, MIER3, NFYB, NFYA, ANP32A, FUBP1, ZNF646, TRAPPC2, PCGF6, ZNF367, NFIC, LCORL, TCEAL1, ELP5, HOMEZ, NFIA, BTF3, TSC22D4, SERTAD3, FOXN2, PURB, MACC1, PURA, FOXK1, HMGB3, DMTF1, COMMD2, PHTF1, SOX5, LCOR | Transcription, nucleus, protein binding, DNA binding, phosphoprotein |
| Group 3 (13.56) | BUB1B, LATS1, CSNK1A1, RPS6KA3, SGK3, LIMK1, IRAK1, PRKCE, CDK6, TESK2, DYRK3, MAP3K1, WNK3, MAP3K2, WNK1, ROCK2, MAP3K7, CDKL2, CIT, ACVR1C, CDK19, SLK, MAP2K3, SNRK, PIM3, SRPK2, SRPK1, MAP3K13, HIPK3, PDIK1L, MAPK7, MKNK2, NEK1, FRK, CSNK2A1 | Kinase activity, transferase, phosphoprotein, binding (protein, ATP, nucleotide), cytoplasm, nucleus, cytosol, protein phosphorylation, proton receptor |
| Group 4 (11.94) | TGIF1, HOMEZ, ZEB2, SATB1 | Transcription activity, nucleus, binding, acetylation, homeobox, phosphoprotein, repressor |
| Group 5 (11.74) | RAPH1, OSBPL3, PLEKHA8, SKAP2, EXOC8, OSBP, SPATA13 | Membrane, transport, cytosol, cytoplasm, protein binding, pleckstrin homology, phosphoprotein |
| Group 6 (11.44) | RLIM, RNF103, TRIM38, BMI1, RFFL, UBR3, RNF6, TRIM33, TRIM59, RNF185, PCGF6, RNF111, MARCH3, CBLL1, RNF11, DTX3L, RSPRY1, TOPORS, TRIM4, TRIM2, RNF141, SCAF11, MYCBP2 | Zinc, zinc finger, binding (metal, protein, ion), ligase activity, phosphoprotein, nucleus, Ubl conjugation pathway, RING |
| Group 7 (11.15) | NCL, CPEB4, RBM27, MYEF2, MSI2, ELAVL4, RBM39, SREK1, SRSF7, HNRNPH1, CPEB3, CELF2, PTBP3, PPIL4, HNRNPA3, SRSF11, HNRNPR | RNA/nucleotide/nucleic binding, protein binding, nucleus, cytoplasm, acetylation, mRNA processing, nucleoplasm |
| Group 8 (9.92) | ZMAT5, MBNL1, SNRNP48, SCAF11 | Spliceosome, metal/zinc/ion binding, protein binding, nucleus, cytoplasm, RNA binding, RNA splicing, mRNA processing, phosphoprotein, zinc finger |
| Group 9 (9.74) | ZNF667, RSF1, ZBTB44, ZBTB8A, PHF20L1, WHSC1L1, ZNF662, ZBTB47, REST, ZNF654, ZNF35, ZNF587, ZNF326, ZNF573, ZNF704, ZNF217, ARID2, ZNF429, ZNF24, RREB1, ZNF277, ZNF207, SNAI1, ZNF268, ZNF460, NR2C2, ZNF200, ZEB2, ZUFSP, SUZ12, ZNF292, TSHZ3, THAP1, SNAI2, ZNF646, ZNF607, HIC2, BCL11B, ZNF652, BCL6, ZNF367, PCGF6, KAT7, GLIS3, ATMIN, PHF20, ADNP, KLF5, KLF9, ZNF264, SP1, GLIS2, KAT6A, ZBTB20, ZNF148, ZNF532, TRPS1, TRIM33, BAZ1B, IKZF3, ZNF451, ZNF440, LCOR, ZBTB38, ZEB1 | Zinc finger, zinc, nucleus, transcription, binding (meta, protein, ion, DNA, nucleic acid), phosphoprotein |
| Group 10 (9.29) | USP7, USP47, USP42, USP34 | Cytosol, cytoplasm, nucleus, DNA repair, ubiquitin activity, protease, hydrolase, phosphoprotein, acetylation |
| Group 11 (9.13) | NR2C2, ESR1, PPARA, NR2F2, NR3C1, HNF4A | Regulation of transcription, acetylation, cytoplasm, nucleus, protein/metal/DNA/ion binding, receptor, lipid metabolic process, activator, phosphoroprotein, disease mutation, nucleoplasm |
| Group 12 (8.74) | SMAD2, SMAD3, SMAD4, SMAD7, SMAD9 | Signalling pathway, binding, cell cycle, transcription, nucleus, cytoplasm, cancer, disease mutation |
| Group 13 (8.55) | RPS4X, RPS7, RPS19, RPS27, RPS2, RPL35A, RPSA, RPL24 | Nucleus, cytoplasm, phosphoprotein, extracellular matrix, binding translation, ribonucleoprotein, ribosomal protein, membrane, cytosol, exosome |
| Group 14 (8.54) | DDX3X, EIF4A2, SMARCA4, DHX33, ATRX, DDX46, DDX55, DDX3Y, CHD9, DDX6 | Cytoplasm, nucleus, binding, phosphoprotein, helicase, hydrolase, ubl conjugation |
| Group 15 (8.26) | TTC38, TTC33, SGTB, FKBP5 | Extracellular exosome, chaperone, acetylation, phosphoprotein, tetratricopeptide, protein binding |
| Group 16 (7.89) | TGIF1, MEIS1, HOXA1, EN2, PBX1, HOXA9, PKNOX1 | Transcription, DNA binding, organism development, homeobox, nucleus |
| Group 17 (7.74) | ANKRD9, CLIP4, RAI14, SOWAHC, HECTD1, ANKRD46, ANKRD13B | Phosphoprotein, Ankyrin |
| Group 18 (7.74) | SETD2, WHSC1, WHSC1L1, TRIM33, SETD1B | Transcription regulation, zinc finger, chromosome, transferase, nucleus, phosphoprotein, isopeptide bond, Ubl conjugation, associated with SET domain |
| Group 19 (7.00) | ARHGEF28, FGD6, RALGPS2, NET1, SPATA13, ARHGEF12 | Cell membrane, cytosol, cytoplasm, signal transduction, Rho guanyl-nucleotide exchange factor, phosphoprotein |
| Group 20 (6.74) | DOCK4, RALGPS2, DOCK7, DOCK10, DOCK5 | Cytoplasm, cell membrane, acetylation, dedicator of cytokinesis, GTPase activity, phosphoprotein, DOCK-homology region, intracellular |
| Group 21 (6.48) | KIF13A, KIF5B, KIF1C, KIF2A, DYNC1LI2 | Membrane, centrosome, methylation, ATPase activity, kinesin, cytoplasm, ATP binding, cytoskeleton, coiled coil, microtube |
| Group 22 (6.13) | AKT2, PIK3CA, HRAS, AKT1, MAPK1, PIK3R1, MAPK9, MAPK8 | Signalling pathway (GnRH, MAPKinase, EGF, PDGF, IGF-1, insulin, CXCR4, Rrk, PI3, ERBB2, Trka receptor, Ras, Jak-STAT, AMPK, ErbB, cAMP, Toll-line receptor), binding, disease, cancer, cytosol, kinase activity, nucleus, cytoplasm, acetylation, infection, apoptosis, |
| Group 23 (5.99) | BMPR2, BMPR1B, BMPR1A, TGFBR2, ACVR1C, ACVR2B, DDR2 | Phosphoprotein, phosphorylation, kinase activity, signalling pathway (Hippo, BMP, regulation of stem cell, TGF-beta), binding (ATP, metal, nucleotide, ion, protein) TGF-beta receptor, phosphorylation, disease mutation, disulphide bond, transferase, receptor, membrane, transmembrane, signal, extracellular |
| Group 24 (5.41) | EGFR, PDGFRA, EPHA4, ERBB3, ERBB2, CSF1R, DDR2, IGF1R | Membrane, transmembrane, receptor, signal, binding (ATP, nucleotide, protein), kinase, signalling pathway (Ras, Rap1, calcium, cancer), wound healing, cancer, endocytosis, transferase, microRNAs in cancer, cytoplasm, phosphorylation activity, glycoprotein, extracellular, cytoplasm, disease mutation |
| Group 25 (5.19) | RASGRP3, RALGPS2, RAPGEF6, RGL2 | Cytoplasm, membrane, signalling pathway (Ras, Rap1,) binding (Ras GTPase, protein) signal transduction, GTPase activity, phosphoprotein, Ras guanine nucleotide exchange factor |
| Group 26 (4.74) | STXBP5, WDR7, WSB1, CORO2A, DCAF10, WDR77, PHIP, BRWD3, GNB4, NBEA, ELP2, DCAF8, FBXW7, TBL1XR1, TAF5 | WD (1, 2,3,4,5,6,7, 40), WD repeat, phosphoprotein |
| Group 27 (4.14) | DUSP5, PTPDC1, DUSP8, DUSP10 | Phosphatase activity, cytoplasm nucleus, nucleoplasm, hydrolase, MAPK signalling pathway, Rhodanese, dephosphorylation |
| Group 28 (3.49) | RHOB, RAB6C, RHOQ, RAB22A, RAB33B, RAB6A, RAB5B, RAP2B, RAB44 | Cytosol, membrane, transport, methylation, GTPase activity, extracellular exosome, binding (protein, nucleotide, GTP, phosphate, lipid), lipoprotein, prenylation |
| Group 29 (3.12) | SOCS5, SOCS4, SOCS3, SOCS6 | Protein binding, growth regulation, regulation of Jak-STAT, signal transduction inhibitor, signalling pathway (STAT, prolactin, cytokine-mediated, insulin), cytoplasm, SOCS box, SH2 domain, Ubl conjugation pathway, intracellular, inflammation response, suppressor of cytokine signalling, type II diabetes mellitus, protein ubiquitination |
| Group 30 (2.77) | LCLAT1, SERINC1, SERAC1, LPGAT1, TMEM147 | Membrane, transmembrane, lipid metabolism, lipid biosynthesis, phospholipid metabolism, phospholipid biosynthesis, protein binding, endoplasmic reticulum membrane |
| Group 31 (2.73) | LRRC20, FBXL2, LRRC57, TBCEL, CEP97, SKP2, FBXL5, VASN, FBXL13, FMOD, GP5, ZYG11B, FBXL3, LRRC1, CNTRL, LRRC2 | Leucine-rich repeat (1, 2, 3, 4, 5, 6, 7, 8), protein binding |
| Group 32 (2.57) | COL4A1, COL3A1, COL5A2, COL5A1, COL1A1 | Extracellular matrix, signal, disease mutation, extracellular region, fibrillar collagen, focal adhesion, collagen, secreted, binding (metal, ion, platelet-derived growth factor), PI3-Akt signalling pathway, calcium, glycoprotein, skin development, disulphide bond, glycosylation, skeletal system development |
| Group 33 (1.50) | IVNS1ABP, KLHL24, KBTBD6, KBTBD7, IPP, KLHL15, KLHL28 | Kelch (1,2,3,4,5,6), kelch repeat, kelch-like protein, protein ubiquitination, ubiquitineous activity, BTB domain, BTB/POZ |
| Group 34 (1.25) | MMP13, PAPPA, MMP10, MMP9, ADAMTS4, MMP2, MMP1 | Zinc, calcium, signal, membrane, extracellular matrix, collagen degradation, hemopexin-like domain, metallopeptidase, glycoprotein, zymogen, protease, hydrolase, disulphide bond, metal binding |
| Group 35 (0.93) | CERS4, SPTLC3, SGPL1, SPTLC2, CERS6 | Transmembrane, metabolic pathway, sphingolipid activity, pyridoxal phosphate, endoplasmic reticulum, ceramide biosynthetic process |
| Group 36 (0.01) | EDNRA, C15orf48, ARMCX3, VOPP1, ANKRD46, TMPPE, SLC2A14, SACM1L, TMEM2, ST6GAL1, FAM20B, SAMD5, SLC31A1, GLRA3, SLC12A5, TMEM178B, BOC, SLC16A10, FGFRL1, TM9SF3, IL13RA1, LIFR, B3GNT5, LMBR1, TMEM170A, IL10RB, PIGX, GALNT6, CNNM3, SLC17A5, DSE, SLC44A1, SGCB, SLC39A9, CERS6, FAXC, FAXDC2, TMEM56, CHST10, TMED4, MCTP1, SLC26A2, TMEM147, B3GALNT1, HTR2C, MRAP2, PGRMC2, BSG, SFXN1, CADM2, SFT2D2, SLC45A4, COX20, PEAR1, TOR1AIP2, CCR7, CCR6, CCR5, CCR1, NCSTN, NETO2, HEPHL1, OR7D2, BTN3A3, GJD2, CYBRD1, PIGN, LRIT3, CLPTM1L, MGAT4A, CDH7, HERPUD2, MXRA7, TMEM245, MEGF9, GPR156, SLMAP, PIGP, HSP40, GXYLT2, TMEM97, SLC5A3, EXT1, MOXD1, SERINC1, SCN2B, CD151, HS3ST3B1, GXYLT1, TNFRSF10B, TMEM120B, ORAI2, OLR1, TNFRSF10D, PTGFR, CD47, CD44, RER1 | Membrane, transmembrane, glycoprotein, cytoplasmic domain, glycosylation |
Figure 3Visualisation of the biological processes (BPs) resulting from the analysis of target genes regulated by hsa-miR-205 associated with HaCaT-derived EVs using Cytoscape (Version 3.2.1).
Figure 4Visualisation of the BPs resulted from the analysis of target genes regulated by a group of four miRNAs (hsa-miR-21, hsa-miR-203, hsa-miR-22 and hsa-miR-143) associated with PKCs using Cytoscape (Version 3.2.1).
Figure 5Common and unique terms associated with HaCaT- and PKC-derived EVs. The reported terms herein are from the 20 most statistically significant GO Terms. The red text indicates common terms associated with the target genes of miRNA from HaCaT- and PKC-derived EVs.
BP terms related to migration.
| Terms | Terms | ||
|---|---|---|---|
|
| |||
| Regulation of cell migration | 0.0033 | Epithelium migration | 0.0382 |
| Negative regulation of cell migration | 0.0301 | Regulation of epithelial cell migration | 0.0398 |
| Epithelial cell migration | 0.0352 | Tissue migration | 0.0465 |
|
| |||
| Regulation of cell migration | 0.0001 | Regulation of mononuclear cell migration | 0.0032 |
| Positive regulation of cell migration | 0.0001 | Regulation of vascular associated smooth muscle cell migration | 0.0063 |
| Positive regulation of epithelial cell migration | 0.0001 | Regulation of blood vessel endothelial cell migration | 0.0088 |
| Regulation of epithelial cell migration | 0.0001 | Regulation of fibroblast migration | 0.0092 |
| Positive regulation of endothelial cell migration | 0.0001 | Regulation of leukocyte migration | 0.012 |
| Regulation of endothelial cell migration | 0.0001 | Positive regulation of vascular associated smooth muscle cell migration | 0.0161 |
| Cell migration | 0.0001 | Leukocyte migration | 0.0169 |
| Positive regulation of mononuclear cell migration | 0.0002 | Thymocyte migration | 0.0192 |
| Regulation of smooth muscle cell migration | 0.0007 | Positive regulation of fibroblast migration | 0.0211 |
| Positive regulation of leukocyte migration | 0.0011 | Regulation of trophoblast cell migration | 0.0411 |
| Negative regulation of cell migration | 0.0011 | Positive regulation of cell migration involved in sprouting angiogenesis | 0.0411 |
| Positive regulation of blood vessel endothelial cell migration | 0.0017 | Dendritic cell migration | 0.0423 |
| Positive regulation of smooth muscle cell migration | 0.0032 | ||
Figure 6Primary dermal fibroblast migration is modulated by PKC-derived EVs but is not dose dependent. HaCaT- or PKC-derived (A,B) APs, (C,D) MVs or (E,F) EXs were added to scratch-wounded primary fibroblast cultures to a final total EV protein concentration of 1 µg, 10 µg or 20 µg/0.1 mL DM as indicated. The fibroblasts were incubated at 5% CO2 and 37 °C and allowed to migrate for 24 h with images captured at 6 hourly intervals. Image analysis was performed using ImageJ and data are presented as the mean percent area of wound coverage in µm2 ± SD, from at least 3 independent biological replicates. Two-way ANOVA and Tukey’s multiple comparison tests were used to evaluate statistical significance, which is denoted as * where p < 0.05; ** p < 0.01; and **** p < 0.0001. AP: Apoptotic bodies; MV: Microvesicles; EX: Exosomes; CT: Control.
Figure 7Primary keratinocyte-derived EXs facilitate migration of dermal fibroblasts in 2D culture. Isolated primary keratinocyte-derived EXs were added to scratch-wounded primary fibroblast cultures to a final total EV protein concentration of 1 µg, 10 µg or 20 µg/0.1mL depleted media. Fibroblasts cultured within depleted media only served as controls. The wounded fibroblast cultures were incubated at 5% CO2 and 37 °C and allowed to migrate for 24 h in the presence or absence of primary keratinocyte-derived EXs with images captured at 6 hourly intervals. Representative images were extracted from the captured IncuCyteTM images at (A1,B1,C1,D1) T = 0 h; (A2,B2,C2,D2) T = 12 h; and (A3,B3,C3,D3) T = 24 h. Images were captured using a 4X objective. The scale bar = 300 µm and the dotted lines represent the wound edge.